Breaking News

Cumberland Pharma Acquires Astellas’ Vaprisol

By Kristin Brooks | March 3, 2014

Assumes responsibility for marketing, distribution and manufacture

Cumberland Pharmaceuticals, Inc. has acquired Vaprisol from Astellas Pharma US, Inc. Vaprisol is one of two branded prescription products indicated for the treatment of hyponatremia, an electrolyte disturbance associated with congestive heart failure, liver failure, kidney failure and pneumonia. The product was developed and registered by Astellas and was launched in 2006. 
 
Cumberland will assume full responsibility for marketing, distribution and manufacture. Cumberland will promote Vaprisol in the U.S. through its hospital sales force, which also features its Caldolor and Acetadote brands.
 
"We believe Vaprisol is an excellent strategic fit with our focus on hospital acute care," said A.J. Kazimi, chief executive officer of Cumberland Pharmaceuticals. "Our immediate plan for Vaprisol is to ensure a smooth transition of the product supply and medical support to current users of the brand. We will then launch our hospital promotion support and are very optimistic about the opportunity that Vaprisol will offer Cumberland."

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks